Format

Send to

Choose Destination
Intern Emerg Med. 2018 Jan;13(1):1-9. doi: 10.1007/s11739-017-1755-0. Epub 2017 Sep 23.

ESC position paper on cardiovascular toxicity of cancer treatments: challenges and expectations.

Author information

1
Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Via Irnerio, 48, 40126, Bologna, BO, Italy.
2
Department of Specialist, Diagnostic and Experimental Medicine, Institute of Cardiology, S.Orsola-Malpighi University Hospital, Alma Mater Studiorum, University of Bologna, Bologna, Italy.
3
Department of Specialist, Diagnostic and Experimental Medicine, Division of Angiology and Blood Coagulation, S.Orsola-Malpighi University Hospital, Alma Mater Studiorum, University of Bologna, Bologna, Italy.
4
Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Via Irnerio, 48, 40126, Bologna, BO, Italy. fabrizio.deponti@unibo.it.

Abstract

The recent position paper of the European Society of Cardiology (ESC) on cardiovascular toxicity of cancer treatments has attracted considerable interest by healthcare professionals, since it is the first concrete help in the difficult task of monitoring and approaching cardiovascular side effects of anticancer treatments. The ESC expert opinion was not intended as a clinical practice guideline; however, it reports major cardiovascular complications grouped into nine categories, addressing current clinical strategies for prevention and mitigation. In this point of view, we discuss key challenges emerging from critical appraisal of the ESC position paper: (1) the wide spectrum of cardiovascular toxicities associated with oncological drugs, focusing on targeted agents, (2) managing strategies in patients with cardiac implantable devices, (3) the underappreciated (but emerging) immune-related cardiovascular toxicities of checkpoint inhibitors, which may also result in severe heart failure and fulminant myocarditis, (4) the evolving role of anticoagulation in oncology, and the evidence supporting (or not) the use of direct-acting oral anticoagulants in cancer-associated thrombosis.

KEYWORDS:

Cardio-oncology; Cardiotoxicity; Direct oral anticoagulants; Immune checkpoint inhibitors; Immuno-vigilance

PMID:
28942550
DOI:
10.1007/s11739-017-1755-0
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center